Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note

Abstract

Background:

In randomized clinical trials, when treatments do not work equally effectively across stratifications of participants, observed event rates may differ from those hypothesized leading to deviations in estimated power.

Objectives:

To investigate the effect of distributions of baseline Expanded Disability Status Scale (EDSS) proportions in relapsing-remitting multiple sclerosis (RRMS) on the trial outcome, confirmed disability progression rate (CDPR), and power.

Methods:

We reported CDPRs in the CombiRx trial by baseline EDSS and by groups (1st (0, 1), 2nd (1.5, 2), 3rd (2.5, 3), and 4th (⩾3.5)) and investigated the effect of different combinations of baseline EDSS proportions on the trial outcome and power.

Results:

There were 244 (25.4%) participants in the 1st group, 368 (38.4%) in the 2nd group, 223 (23.3%) in the 3rd group, and 124 (12.9%) in the 4th group with CDPRs of 40.1%, 13.9%, 11.2%, and 16.9%, respectively. Both CDPR and power increased when the proportion of the 1st group increased in hypothetical trials with equal sample sizes in each arm, and a 10% increase in the 1st group led to a 5% increase in power.

Conclusion:

Various baseline EDSS proportions yielded different CDPRs and power, suggesting caution in interpretation of treatment effects across trials that enrolled participants with different proportions of baseline EDSS.

Keywords

Multiple sclerosis Expanded Disability Status Scale relapsing-remitting multiple sclerosis confirmed disability progression rate

Get full access to this article

View all access options for this article.

References

Reingold

McFarland

Petkau

. The growing need for alternative clinical trial designs for multiple sclerosis. In: Cohen

Rudick

(eds) Multiple Sclerosis Therapeutics (pp. 253–260). Cambridge: Cambridge University Press, 2011.

Riddell

Zhao

Petkau

. An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context. Stat Methods Med Res 2016; 25: 1330–1345.

Lublin

Cofield

Cutter

. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013; 73: 327–340.

Lindsey

Scott

Lynch

. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Mult Scler Relat Disord 2012; 1: 81–86.

Cofield

Cutter

Lublin

. Variability in the EDSS: What does it mean for progression? Chicago: American Academy of Neurology, 2008, pp. 12–19.

Harding

Wardle

Moore

. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatr 2015; 86: 13–19.

Goldman

Motl

Rudick

. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 229–239.

Cohen

Coles

Arnold

. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828.

Comi

Jeffery

Kappos

. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366: 1000–1009.

10.

O’Connor

Wolinsky

Confavreux

. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293–1303.

11.

O’Connor

Filippi

Arnason

. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889–897.

12.

Kappos

Freedman

Polman

. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987–997.